Welcome to our dedicated page for Serina Therapeutics news (Ticker: $ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.
Serina Therapeutics reported its Q1 2024 financial results, highlighting significant developments. The company is advancing its lead drug candidate, SER-252, for advanced Parkinson’s Disease, with plans to submit an IND application in 2025. Serina completed its merger with AgeX Therapeutics and appointed Dr. Simba Gill as Executive Chairman. Financially, Serina increased its line of credit by $2.4 million and received an additional $525,000 in May 2024. Cash and equivalents totaled $8.8 million, with a net loss of $9.4 million for Q1 2024. Revenues were $5,000, and operating expenses increased to $2.3 million from $1 million in the same period in 2023. The company expressed concerns about its ability to meet financial obligations over the next year.
